

Subject: RE: Launch Package: LinkSPINE \$20M Private Placement  
From: Stewart Oldfield <[REDACTED]>  
Date: Tue, 24 Jul 2018 11:48:40 -0400  
To: Oliver Rothauser <[REDACTED]>,  
Zack Tax <[REDACTED]>

Also to the Shamrock guys. Greg Martin and David Robbins

From: Stewart Oldfield  
Sent: Tuesday, July 24, 2018 11:48 AM  
To: Oliver Rothauser <[REDACTED]>; Zack Tax <[REDACTED]>  
Subject: FW: Launch Package: LinkSPINE \$20M Private Placement

Please send to Erin Enright and Stuart Essig at Prettybrook Partners. Thanks

[REDACTED]

[REDACTED]

From: Martin Zeman  
Sent: Tuesday, July 24, 2018 9:32 AM  
To: 'Paul Barrett ([REDACTED])' <[REDACTED]>  
Cc: Stewart Oldfield <[REDACTED]>; Zack Tax <[REDACTED]>;  
Oliver Rothauser <[REDACTED]>  
Subject: Launch Package: LinkSPINE \$20M Private Placement

Paul,

This comes from our "private markets desk" – you met Oliver end of last year around lunch at Dan's club.

Do you think Jeffrey would be interested?

-----

A \$20 million private placement we are engaged on with our Investment Bank for a medical device company, LinkSPINE. LinkSPINE is targeting the outpatient market for spinal surgery with two products: 1) a novel, minimally invasive midline kit providing physicians procedural flexibility and efficiency which is specifically designed for use in outpatient facilities 2) TargetLINK, a chip-based navigation software platform to facilitate the placement of screws while reducing radiation exposure to physicians and patients during surgery by 80-90%.

The Company's consumable products are already FDA approved for commercial use and the Company expects their TargetLINK product to receive FDA approval in the next 9 months.

The Company has been incubated by the Link Group, a German based orthopedics firm with an established track record of successfully bringing medical device products to market. To date, they have invested \$25 million into LinkSPINE.

Use of proceeds for this round are being allocated to build a robust commercial sales and marketing infrastructure for their products.

Attached you can find a brief teaser on the Company and if you are interested in learning more we are able to facilitate an introductory call with our Investment Bank to take a deeper dive into both the products and spinal surgery market.

-----

Martin

{cid:image001.gif@01D259D5.3E2DF0F0}

Martin Zeman  
Director | Key Client Partners

Deutsche Bank Wealth Management  
DB Securities Inc

345 Park Avenue, 10154-0004 New York, NY, USA

Tel. [REDACTED]

Mobile [REDACTED]

Email [REDACTED]

KCP products and services are intended and available only for persons who are sophisticated institutional investors within the meaning of the FINRA Rule 4512(C)(3), and who are capable of evaluating the strategies, characteristics and investment risks of, and exercising independent judgment in evaluating, the ideas and products discussed herein. Trades and transactions are subject to relevant internal approvals of DBSI or its affiliates prior to execution, and the execution of any transaction or idea discussed herein is conditional on your becoming a client of Deutsche Bank. Key Client Partners (KCP) products, investment ideas and solutions and related matters discussed herein are provided for discussion purposes only, and strictly on a non-advisory basis. The KCP Americas desk does not provide investment advice. The information set forth herein is confidential and personal to you and is being presented for your information and for discussion purposes only. Any reproduction and/or redistribution thereof (in whole or in part) or disclosure of its content without our written consent is strictly forbidden. This communication does not create any legally binding obligation on the part of DBSI or any of its affiliates.